Zhenyu Ji

Zhenyu Ji

Auto-generated profile, based on publicly available information

Zhenyu Ji

Wellman Center for Photomedicine and Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
ZJZhenyu Ji
Zhenyu Ji
CNChing-Ni Njauw
Ching-Ni Njauw
SGSamantha Guhan
Samantha Guhan
RKRaj Kumar
Raj Kumar
BRBobby Reddy
Bobby Reddy
HTHensin Tsao
Hensin Tsao

18 March 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
SGSamantha M. Guhan
Samantha M. Guhan
MSMichael Shaughnessy
Michael Shaughnessy
ARAnpuchchelvi Rajadurai
Anpuchchelvi Rajadurai
MTMichael Taylor
Michael Taylor
RKRaj Kumar
Raj Kumar
HTHensin Tsao
Hensin Tsao

1 April 2025 in Bioactive Materials
Verified
Journal Article
Open access
KPKishwor Poudel
Kishwor Poudel
ZJZhenyu Ji
Zhenyu Ji
CNChing-Ni Njauw
Ching-Ni Njauw
ARAnpuchchelvi Rajadurai
Anpuchchelvi Rajadurai
BBBrijesh Bhayana
Brijesh Bhayana
HTHensin Tsao
Hensin Tsao
Cancer nanovaccines hold the promise for personalization, precision, and pliability by integrating all the elements essential for effective immune stimulation. An effective immune response requires communication and interplay between antigen-presenting cells (APCs), tumor cells, and immune cells to stimulate, extend, and differentiate antigen-specific and non-specific anti-tumor immune cells. The versatility of nanomedicine can be adapted to deliver both immunoadjuvant payloads and antigens from the key players in immunity (i.e., APCs and tumor cells). The imperative for novel cancer medicine is particularly pressing for less common but more devastating KIT-mutated acral and mucosal melanomas that are resistant to small molecule c-kit and immune checkpoint inhibitors. To overcome this challenge, we successfully engineered nanotechnology-enabled hybrid biomimetic nanovaccine (HBNV) comprised of membrane proteins (antigens to activate immunity and homing/targeting ligand to tumor microenvironment (TME) and lymphoid organs) from fused cells (of APCs and tumor cells) and immunoadjuvant. These HBNVs are efficiently internalized to the target cells, assisted in the maturation of APCs via antigens and adjuvant, activated the release of anti-tumor cytokines/inhibited the release of immunosuppressive cytokine, showed a homotypic effect on TME and lymph nodes, activated the anti-tumor immune cells/downregulated the immunosuppressive immune cells, reprogram the tumor microenvironment, and showed successful anti-tumor therapeutic and prophylactic effects.

16 December 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
YKYuanyuan Kang
Yuanyuan Kang
ZJZhenyu Ji
Zhenyu Ji
HLHe Li
He Li
HTHensin Tsao
Hensin Tsao

1 May 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
CNChing-Ni Njauw
Ching-Ni Njauw
ZJZhenyu Ji
Zhenyu Ji
DPDuc Minh Pham
Duc Minh Pham
ASAntoine Simoneau
Antoine Simoneau
RKRaj Kumar
Raj Kumar
HTHensin Tsao
Hensin Tsao

14 December 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
DUDmitrii Usoltsev
Dmitrii Usoltsev
CNChing-Ni Njauw
Ching-Ni Njauw
ZJZhenyu Ji
Zhenyu Ji
RKRaj Kumar
Raj Kumar
ASAlexey Sergushichev
Alexey Sergushichev
HTHensin Tsao
Hensin Tsao